Literature DB >> 12631018

Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.

Hans C Fledelius1.   

Abstract

PURPOSE: To evaluate through a longitudinal study the effects on visual fields of long-term vigabatrin medication in patients with partial epilepsy and to discuss visual field screening strategies.
METHODS: A total of 26 patients aged 14-68 years with a mean history of vigabatrin medication of 8.5 years (range 2-14 years) were followed by manual kinetic Goldmann perimetry (objects IV,4 and I,4) for 6-26 months (mean value 12.3 months). At time zero and at follow-up, each patient was assigned a "pooled" averaged value, as a linear percentage of normal isopter position, for the two objects as tested nasally and temporally in the five most horizontal meridians on the Goldmann chart. Twelve eyes from nine adults (age 24-60 years) served as controls.
RESULTS: Constrictions were recorded in 24 of 26 patients at baseline. Averaged isopters ranged from 8% to 96% of the controls' averaged isopter positions. Median values of 71.5% and 60.5% for large and small objects, respectively, indicated that the smaller object was more sensitive to visual field constriction. There was no difference in the degree of constriction between nasal and temporal hemifields. Significant improvement in the visual field (mean gain 13.6% units) was seen in the eight patients who underwent full drug withdrawal. No similar improvement was seen in the 12 patients still on full dose or the six with reduced intake.
CONCLUSIONS: Most Danish patients on long-term vigabatrin medication have suffered some visual field loss. Contrary to most clinical evidence so far, the present follow-up study indicates some reversibility of visual field loss after drug withdrawal. Kinetic Goldmann perimetry appears to be a fair alternative to computerized static perimetry techniques for screening and following vigabatrin-treated patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631018     DOI: 10.1034/j.1600-0420.2003.00023.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  10 in total

1.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

2.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

3.  Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.

Authors:  Dorothea Besch; Ulrich Schiefer; Nicole Eter; Roland Burth; Christian E Elger; Manfred Spitznas; Klaus Dietz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-05       Impact factor: 3.117

Review 4.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 5.  Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

Authors:  Peter Zwanzger; Rainer Rupprecht
Journal:  J Psychiatry Neurosci       Date:  2005-05       Impact factor: 6.186

6.  Vigabatrin and visual field defects in pediatric epilepsy patients.

Authors:  Su Jeong You; HyoSook Ahn; Tae-Sung Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

7.  Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.

Authors:  John M Wild; Catherine Chiron; Hyosook Ahn; Michel Baulac; Joseph Bursztyn; Enrico Gandolfo; Ivan Goldberg; Francisco Javier Goñi; Florence Mercier; Jean-Philippe Nordmann; Avinoam B Safran; Ulrich Schiefer; Emilio Perucca
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

Review 8.  Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.

Authors:  Anand Iyer; Richard Appleton
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.022

9.  Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.

Authors:  Ulrika Kjellström; Monica Lövestam-Adrian; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

10.  Relationship between the area of isopters and Vigabatrin dosage during two years of observation.

Authors:  Katarzyna Nowomiejska; Marian Jedrych; Agnieszka Brzozowska; Konrad Rejdak; Tomasz Zarnowski; Michael J Koss; Katarzyna Ksiazek; Piotr Ksiazek; Ryszard Maciejewski; Anselm G Juenemann; Ulrich Schiefer; Robert Rejdak
Journal:  BMC Ophthalmol       Date:  2014-04-30       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.